ChIP-BIT2

ChIP-BIT2 identifies protein–DNA binding events from ChIP-seq data, emphasizing detection of weak binding sites at promoters and enhancers.


Key Features:

  • Bayesian integration via mixture model: Employs a Bayesian integration approach using a mixture model to combine protein-specific and control ChIP-seq data.
  • Weak binding detection: Differentiates weakly bound regions from amplified background DNA to improve detection of low-enrichment sites.
  • Genomic localization: Predicts both strong and weak protein binding sites across genomic locations, including promoters and enhancers.
  • Target gene prediction: Simultaneously predicts target genes associated with promoter-bound binding sites.
  • Peak calling: Functions as a peak caller for ChIP-seq data to identify enriched regions.
  • Validation: Validated using benchmark regions and large-scale ENCODE ChIP-seq datasets.

Scientific Applications:

  • Detection of regulatory binding sites: Enables detection of weak protein–DNA interactions at promoters and enhancers that may regulate gene expression.
  • Gene target assignment: Predicts promoter-bound target genes to link binding events to gene regulation.
  • Regulatory network analysis: Extends the collection of known binding sites to support analysis of gene expression regulation and regulatory networks.
  • Large-scale ChIP-seq analysis: Applicable to genome-wide ChIP-seq datasets such as ENCODE for comprehensive binding site discovery.

Methodology:

Uses Bayesian integration via a mixture model to combine protein-specific and control ChIP-seq data for distinguishing true binding signals from background.

Topics

Details

Tool Type:
command-line tool
Operating Systems:
Linux
Programming Languages:
C++
Added:
6/14/2021
Last Updated:
8/20/2021

Operations

Publications

Chen X, Shi X, Neuwald AF, Hilakivi-Clarke L, Clarke R, Xuan J. ChIP-BIT2: a software tool to detect weak binding events using a Bayesian integration approach. BMC Bioinformatics. 2021;22(1). doi:10.1186/s12859-021-04108-5. PMID:33858322. PMCID:PMC8051094.

PMID: 33858322
PMCID: PMC8051094
Funding: - National Cancer Institute: 149147, 149653, 164384 - National Institute of General Medical Sciences: 125878